RNAi drug Kylo-11 cuts heart disease risk by lowering Lp(a) 25%

New research in The Lancet shows Kylo-11, an RNA interference therapeutic, reduced lipoprotein(a) (Lp(a)) concentrations by 20-25%. This modest drop significantly cuts the risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis. It points to a new way to target a long-neglected heart risk factor.